Navigation Links
Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
Date:7/24/2013

SUNNYVALE, Calif., July 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its second quarter ended June 30, 2013 after the NASDAQ Market closes on Wednesday, July 31, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day.

Conference call and webcast details:

Date: July 31, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877) 303-7908
International: (678) 373-0875

Replay Number (Toll Free): (855) 859-2056
Replay Number (International): (404) 537-3406
Conference ID #: 23863642

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercia
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Reports First Quarter 2013 Results
2. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
3. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
4. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
5. Pharmacyclics, Inc. Prices Public Offering of Common Stock
6. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
7. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
8. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
9. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... and BOSTON , January 23, ... drug discovery and development company, is delighted to announce that ... been awarded to Miles Congreve (Vice President of ... and Malcolm Weir (Chief Executive Officer and co-founder) ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Dr. Joan Fallon , founder and CEO of Curemark, ... on the treatment of neurological diseases, presented at the Keystone Symposia meeting, ... in Snowbird, Utah .   , ... Fallon presented on "The Role of Protein Assimilation and Utilization ...
... SAN FRANCISCO , May 3 SARcode ... novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today ... study evaluating topical SAR 1118 ophthalmic solution ... sicca). The study results were presented at the Dry ...
Cached Medicine Technology:Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism 2Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism 3SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye 2SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... (Amex: ILI ), a company focusing on ... Lewis H. Bender, Chief Executive,Officer, will present at ... on January 30th at 11:45AM to be held ... In addition, Kenneth S. Kornman, DDS., Ph.D. ...
... for an End to ... NEW YORK, Jan. 28 Legal Momentum, in ... United States,(SIECUS) and the Center for Health and Gender ... 29) and at the University of,Southern Maine Portland campus ...
... is a Survivor,s Story of Overcoming ... Adversity and Giving of Oneself, WASHINGTON, Jan. 28 On ... was raped, beaten and held hostage,at gunpoint for two hours. In her ... victim:, "They took my money, my credit cards and my body. ...
... Extension in Europe for the Treatment of ... Patients with Metastatic Colorectal Cancer, BASEL, Switzerland, Jan. ... given its approval for the significantly,wider use of its anti-angiogenic ... new broader label will now allow Avastin to be used ...
... Local assisted living facility in violation of "Nicole,s Law" designed to ... protect ... at Atria Senior Living? That,s what members of the Campaign to ... Place facility at 15 Stevens Street in Andover was found in,violation ...
... in Western society are suffering from auto-immune diseases. Discovering ... important step in the search for targeted medicines. VIB ... Leuven joined forces and have elucidated the function of ... They are the first to show that MALT1 is ...
Cached Medicine News:Health News:Interleukin Genetics, Inc. Management to Present at Healthcare Conferences 2Health News:Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses 2Health News:Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses 3Health News:IF You Had Survived a Brutal Rape at Gunpoint, Would You Teach Aerobics to Convicted Felons? 2Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 2Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 3Health News:Activists Raise Alarm for Seniors, Deliver Carbon Monoxide Detectors to Atria Marland Place 2Health News:A major step toward a more targeted treatment for auto-immune diseases? 2
... The latest in Canons DR innovations, ... DR system. With a compact and lightweight ... positioned, just like conventional screen-film cassettes. It ... that are difficult to get with fixed ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... 227 T is a quadripolar ... cardiac pacing and monitoring during ... TME 227 T features tines ... which allows safe and easy ...
Medicine Products: